Novel Tretinoin Lotion Safe, Effective for Acne Treatment in Hispanic Patients
Skin irritation and dryness, as well as pigmentation changes are key concerns in this population when developing a treatment plan.
Fall Clinical Dermatology Conference 2018
Lower Concentration Halobetasol Lotion as Effective as Cream for Psoriasis
Halobetasol propionate 0.01% was associated with a 22.3% improvement in body surface area, compared with 20.9% in the 0.05% concentration.
Early Results Indicate Prolonged Improvements in Atopic Dermatitis With GBR 830
GBR 830 may be an effective and safe long-term treatment option for patients with moderate to severe atopic dermatitis.
Brodalumab Effective for Long-Term Clearance of Psoriasis
Brodalumab was shown to be safe and effective for long-term clearance of moderate to severe psoriasis.
Hydrogen Peroxide Topical Solution Effective for Seborrheic Keratosis
A-101 40 is the first and only FDA-approved topical drug for raised seborrheic keratosis.
Personal Care Products: What Patients Should Know About Shaving, Detergents, and More
Detergents labeled as dye- and fragrance-free may be the best option for certain patients.
Skin Clearance Rates in Plaque Psoriasis Maintained Long-Term With Guselkumab
Tremfya, a human anti-interleukin (IL)-23 monoclonal antibody, is a subcutaneous injection currently approved to treat adults with moderate to severe plaque psoriasis,
Topical Minocycline Foam Safe, Effective for Moderate to Severe Acne Vulgaris
Currently, oral minocycline and doxycycline are first-line therapies for this condition but are associated with potentially serious systemic adverse effects.
Halobetasol, Tazarotene Combination Therapy Demonstrate Lasting Efficacy for Plaque Psoriasis
Among patients who were treated with HP/TAZ lotion, 57.3% experienced treatment success in the course of the study.
Tretinoin Lotion Demonstrates Safety, Efficacy in Treating Preadolescent Acne
Scaling, stinging, and burning increased slightly during weeks 0 to 4 but were transient.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...